ES2536638T3 - Alteración dirigida de ADN - Google Patents

Alteración dirigida de ADN Download PDF

Info

Publication number
ES2536638T3
ES2536638T3 ES11791641.1T ES11791641T ES2536638T3 ES 2536638 T3 ES2536638 T3 ES 2536638T3 ES 11791641 T ES11791641 T ES 11791641T ES 2536638 T3 ES2536638 T3 ES 2536638T3
Authority
ES
Spain
Prior art keywords
dna sequence
oligonucleotide
mismatch
double
directed dna
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES11791641.1T
Other languages
English (en)
Inventor
Paul Bundock
Franck Lhuissier
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Keygene NV
Original Assignee
Keygene NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Keygene NV filed Critical Keygene NV
Application granted granted Critical
Publication of ES2536638T3 publication Critical patent/ES2536638T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/102—Mutagenizing nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1082—Preparation or screening gene libraries by chromosomal integration of polynucleotide sequences, HR-, site-specific-recombination, transposons, viral vectors

Landscapes

  • Genetics & Genomics (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Virology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Procedimiento para la alteración dirigida de una secuencia de ADN aceptor de doble cadena que comprende una primera secuencia de ADN y una segunda secuencia de ADN que es el complemento de la primera secuencia de ADN, comprendiendo el procedimiento combinar la secuencia de ADN aceptor de doble cadena con un oligonucleótido donante, en el que el oligonucleótido comprende al menos un dominio que es capaz de hibridarse a la primera secuencia de ADN, cuyo dominio comprende o está directamente adyacente a al menos un desapareamiento con respecto a la primera secuencia de ADN, y en el que dicho al menos un desapareamiento se encuentra como máximo 2 nucleótidos, preferiblemente como máximo 1 nucleótido del extremo 3' de dicho oligonucleótido, lo más preferiblemente dicho al menos un desapareamiento está en el extremo 3' del oligonucleótido, en el que el procedimiento no es para el tratamiento de un cuerpo humano o animal mediante terapia o para modificar la identidad genética de la línea germinal de seres humanos.

Description

imagen1
imagen2
imagen3
imagen4
imagen5
imagen6
imagen7
imagen8
imagen9
imagen10
imagen11
imagen12
imagen13
imagen14
imagen15

Claims (1)

  1. imagen1
    imagen2
ES11791641.1T 2010-12-02 2011-11-25 Alteración dirigida de ADN Active ES2536638T3 (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US41917910P 2010-12-02 2010-12-02
US419179P 2010-12-02
NL2005808 2010-12-03
NL2005808 2010-12-03
PCT/NL2011/050804 WO2012074385A1 (en) 2010-12-02 2011-11-25 Targeted alteration of dna

Publications (1)

Publication Number Publication Date
ES2536638T3 true ES2536638T3 (es) 2015-05-27

Family

ID=44193925

Family Applications (2)

Application Number Title Priority Date Filing Date
ES14195788.6T Active ES2588482T3 (es) 2010-12-02 2011-11-25 Alteración dirigida de ADN
ES11791641.1T Active ES2536638T3 (es) 2010-12-02 2011-11-25 Alteración dirigida de ADN

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ES14195788.6T Active ES2588482T3 (es) 2010-12-02 2011-11-25 Alteración dirigida de ADN

Country Status (11)

Country Link
US (1) US9150854B2 (es)
EP (2) EP2857512B1 (es)
JP (1) JP6084929B2 (es)
CN (1) CN103459596B (es)
AU (1) AU2011337323B2 (es)
CA (1) CA2819423C (es)
DK (2) DK2646549T3 (es)
ES (2) ES2588482T3 (es)
HU (1) HUE030490T2 (es)
IL (1) IL226536A (es)
WO (1) WO2012074385A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2646550T3 (en) 2010-12-02 2015-05-26 Keygene Nv Targeted DNA modification with oligonucleotides
US20150064149A1 (en) * 2013-09-04 2015-03-05 Mice With Horns, LLC. Materials and methods for correcting recessive mutations in animals
WO2016105185A1 (en) 2014-12-22 2016-06-30 Keygene N.V. Plant callus populations
WO2018115389A1 (en) 2016-12-22 2018-06-28 Keygene N.V. Methods of targeted genetic alteration in plant cells
SG11202002481RA (en) * 2017-09-19 2020-04-29 Tropic Biosciences Uk Ltd Modifying the specificity of non-coding rna molecules for silencing gene expression in eukaryotic cells
EP3821008A1 (en) 2018-07-12 2021-05-19 Keygene N.V. Type v crispr/nuclease-system for genome editing in plant cells
EP3874048A1 (en) 2018-11-01 2021-09-08 Keygene N.V. Dual guide rna for crispr/cas genome editing in plants cells

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US579597A (en) 1897-03-30 Apparatus for heating blooms or other articles of metal
US5556747A (en) * 1990-07-09 1996-09-17 E. R. Squibb & Sons, Inc. Method for site-directed mutagenesis
US6136601A (en) 1991-08-21 2000-10-24 Epoch Pharmaceuticals, Inc. Targeted mutagenesis in living cells using modified oligonucleotides
US5594121A (en) 1991-11-07 1997-01-14 Gilead Sciences, Inc. Enhanced triple-helix and double-helix formation with oligomers containing modified purines
US5731181A (en) 1996-06-17 1998-03-24 Thomas Jefferson University Chimeric mutational vectors having non-natural nucleotides
ES2192672T3 (es) 1996-11-18 2003-10-16 Takeshi Imanishi Nuevos analogos de nucleotidos.
JP3756313B2 (ja) 1997-03-07 2006-03-15 武 今西 新規ビシクロヌクレオシド及びオリゴヌクレオチド類縁体
JP4236812B2 (ja) 1997-09-12 2009-03-11 エクシコン エ／エス オリゴヌクレオチド類似体
US6010907A (en) 1998-05-12 2000-01-04 Kimeragen, Inc. Eukaryotic use of non-chimeric mutational vectors
KR20020013513A (ko) 1999-03-18 2002-02-20 추후제출 Ｘｙｌｏ-ｌｎａ 유사체
US7053207B2 (en) 1999-05-04 2006-05-30 Exiqon A/S L-ribo-LNA analogues
US6936467B2 (en) 2000-03-27 2005-08-30 University Of Delaware Targeted chromosomal genomic alterations with modified single stranded oligonucleotides
EP1268768A2 (en) 2000-03-27 2003-01-02 University Of Delaware Targeted chromosomal genomic alterations with modified single stranded oligonucleotides
AU2001263271A1 (en) 2000-05-17 2001-11-26 University Of Delaware Plant gene targeting using oligonucleotides
US20020119570A1 (en) 2000-09-25 2002-08-29 Kyonggeun Yoon Targeted gene correction by single-stranded oligodeoxynucleotides
WO2003013226A2 (en) 2001-08-09 2003-02-20 Cibus Genetics Non-transgenic herbicide resistant plants
EP1446503A2 (en) 2001-09-27 2004-08-18 University Of Delaware Composition and methods for enhancing oligonucleotide-directed nucleic acid sequence alteration
WO2006064813A1 (ja) * 2004-12-13 2006-06-22 National University Corporation Hokkaido University 核酸構築物及びそれを利用した標的領域への変異導入方法
WO2007073149A1 (en) 2005-12-22 2007-06-28 Keygene N.V. Alternative nucleotides for improved targeted nucleotide exchange
EP2167660A1 (en) * 2007-06-22 2010-03-31 Keygene N.V. Targeted nucleotide exchange with improved modified oligonucleotides
CN102119226B (zh) * 2008-08-12 2013-10-30 霍夫曼-拉罗奇有限公司 校对引物延伸
DK2646550T3 (en) 2010-12-02 2015-05-26 Keygene Nv Targeted DNA modification with oligonucleotides

Also Published As

Publication number Publication date
CA2819423A1 (en) 2012-06-07
EP2646549A1 (en) 2013-10-09
JP2014500727A (ja) 2014-01-16
ES2588482T3 (es) 2016-11-03
DK2646549T3 (en) 2015-05-26
AU2011337323A2 (en) 2013-07-11
HUE030490T2 (en) 2017-05-29
US20140004607A1 (en) 2014-01-02
US9150854B2 (en) 2015-10-06
AU2011337323B2 (en) 2015-11-26
CN103459596A (zh) 2013-12-18
EP2857512B1 (en) 2016-06-29
DK2857512T3 (en) 2016-10-03
AU2011337323A1 (en) 2013-06-20
EP2857512A1 (en) 2015-04-08
IL226536A (en) 2016-03-31
EP2646549B1 (en) 2015-02-18
JP6084929B2 (ja) 2017-02-22
CA2819423C (en) 2020-12-22
WO2012074385A1 (en) 2012-06-07
CN103459596B (zh) 2016-12-14

Similar Documents

Publication Publication Date Title
ES2536638T3 (es) Alteración dirigida de ADN
MX2023008478A (es) Nucleótidos modificados con 5´-ciclo-fosfonato.
MX2017014806A (es) Conjugados oligonucleotido- peptido.
CL2018000119A1 (es) Compuestos pirazolo[1,5-a]piridina sustituidos como inhibidores de quinasa de ret.
CL2014000210A1 (es) Una composicion de prodroga que comprende al menos un conjugado de metilfenidato; kit farmaceutico que la comprende, util para el tratamiento de una enfermedad o condicion que requiere estimulacion del sistema nervioso tal como un trastorno de hiperactividad con deficit de atencion y depresion.
ECSP10010618A (es) Análogos carba - nucleósidos para tratamiento antiviral
MX374896B (es) Compuestos con actividad anticáncer.
ES2536640T3 (es) Alteración dirigida de ADN con oligonucleótidos
MX2020012652A (es) Oligonucleotido bicatenario especifico del gen de anfirregulina y composicion para prevenir y tratar enfermedades relacionadas con la fibrosis y enfermedades respiratorias, que comprende el mismo.
AR090465A1 (es) Formas solidas de un profarmaco de nucleotidos de tiofosforamidato
AR081209A1 (es) Tratamiento de enfermedades relacionadas con la proteina 11 del tipo linfoma 2 de celulas b, (bcl2, bcl2l11) mediante la inhibicion del transcripto antisentido natural a bcl2l11
MX366660B (es) Composiciones de arni contra el componente c5 del complemento y métodos para su uso.
GT201500330A (es) Composiciones y métodos de uso de interferencia de arn en serpina 1
EA201400990A1 (ru) Ингибиторы диацилглицеринацилтрансферазы 2
CR20110441A (es) Preparaciones para la sincronicación de ciclo estral y protocolos sin cidr efectivos.
HN2011002480A (es) Combinaciones de principios activos nematicidas, insecticidas y acaricidas que comprenden piridiletilbenzamidad e insecticidas.
UA109650C2 (xx) Біс-арилзв'язані арилтриазолони та їх застосування
TR201818825T4 (tr) Kardi̇yak hi̇pertrofi̇ni̇n tedavi̇si̇ne ve tanisina yöneli̇k lncrnalar
AR113725A1 (es) Una composición de alimento para prevenir o tratar la enfermedad de necrosis hepatopancreática aguda (ahpnd) o el síndrome de la mancha blanca (wss), que comprende una cepa de bacillus subtilis, una cepa de bacillus pumilus y una cepa de bacillus licheniformis como principios activos
ES2673406T3 (es) Alfa-derivados de ácidos grasos cis-monoinsaturados para uso como medicamentos en el tratamiento de la diabetes
AR114148A2 (es) Composición terapéutica saborizada basada en arcilla
BR112017013765A2 (pt) métodos para uso de oligonucleotídeos antisense smad7
AR083445A1 (es) siARN CONTRA LA FIBROSIS
UY30042A1 (es) Nuevos derivados de alquilfosfolípidos con citotoxicidad reducida y usos de los mismos.
ES2621824T3 (es) Uso de MicroRNA-199B-5P en el campo médico y de diagnóstico